Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Hypereosinophilic Syndrome Clinical Trial

Official title: Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders

Status Recruiting

Clinical Trial Summary

This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine the overall hematologic response rate to ruxolitinib in patients with hypereosinophilic syndrome and primary eosinophilic disorders.

SECONDARY OBJECTIVES:

I. To determine safety profile of ruxolitinib in patients with hypereosinophilic syndrome and primary eosinophilic disorders.

II. To determine the proportion of patients on corticosteroids who are able to become corticosteroid-independent and/or reduce the dose by >= 50%.

III. To evaluate the duration of response (DoR). IV. To evaluate the time-to-response (TTR). V. To evaluate progression-free survival (PFS) and overall survival. ;

Related Conditions & MeSH terms

• BCR-JAK2 Fusion Protein Expression
• Blasts 20 Percent or Less of Peripheral Blood White Cells
• Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
• Blasts More Than 5 Percent of Peripheral Blood White Cells
• Blasts Under 20 Percent of Bone Marrow Nucleated Cells
• Chronic Eosinophilic Leukemia, Not Otherwise Specified
• Eosinophilia
• Hepatomegaly
• Hypereosinophilic Syndrome
• JAK2 Gene Mutation
• Splenomegaly
• Syndrome
• TEL-JAK2 Fusion Protein Expression

• NCT number: NCT03801434
• Study type: Interventional
• Source: Stanford University
• Contact: Tiffany Nguyen
• Phone: 650-725-9167
• Email: tnguye10@stanford.edu
• Status: Recruiting
• Phase: Phase 2
• Start date: November 15, 2019
• Completion date: November 30, 2025